239 related articles for article (PubMed ID: 11136569)
1. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
4. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Pedersen H; Grøndahl-Hansen J; Francis D; Osterlind K; Hansen HH; Danø K; Brünner N
Cancer Res; 1994 Jan; 54(1):120-3. PubMed ID: 8261432
[TBL] [Abstract][Full Text] [Related]
5. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Foekens JA; Buessecker F; Peters HA; Krainick U; van Putten WL; Look MP; Klijn JG; Kramer MD
Cancer Res; 1995 Apr; 55(7):1423-7. PubMed ID: 7882345
[TBL] [Abstract][Full Text] [Related]
7. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
[TBL] [Abstract][Full Text] [Related]
9. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
11. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
Conese M; Blasi F
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
[TBL] [Abstract][Full Text] [Related]
13. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Jankun J; Merrick HW; Goldblatt PJ
J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
16. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
17. Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Kobayashi H; Moniwa N; Gotoh J; Sugimura M; Terao T
Cancer Res; 1994 Jan; 54(1):261-7. PubMed ID: 8261450
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
20. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
